Multi-gene panel testing increases yield of surgically-actionable results among breast cancer patients
TOP 12 ABSTRACT
Multigene Panel Testing (MGPT) increases the identification of surgically-actionable mutations for breast and other cancers, beyond BRCA1/2, by 6.45%.
With MGPT (excluding BRCA1/2) an additional 3.07% of patients were positive for PTEN or TP53, who may be considered for risk reducing mastectomy (RRM) as a treatment option.
Based on NCCN guidelines, our studies also shows that excluding BRCA1/2 an additional 54.22% of mutation carries could consider RRM in the context of their family history of breast cancer.